Type 2 Diabetes Trial, Recruiting NCT05884775 Sponsor: NYU Langone Health Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Type 2 Diabetes Trial, Recruiting

NCT05884775
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For healthcare providers:

  • Full-time primary care doctors or nurse practitioners who work at one of the participating health centres or group practices
  • Providers who care for at least five patients diagnosed with type 2 diabetes

For patients:

  • People who have been diagnosed with type 2 diabetes for at least 6 months
  • People whose type 2 diabetes is not well controlled, meaning a specific blood sugar measurement (HbA1c) was above 7% on at least two medical visits in the past year
  • People who speak English or Spanish fluently
  • People who are willing to send and receive text messages
  • People who are 18 years of age or older

Who may not be able to join:

  • People who are unable or unwilling to give their formal agreement to take part in the study
  • People who have serious kidney problems, kidney failure, are on dialysis, or have had a kidney transplant, as recorded in their medical records
  • People who have a significant mental health condition or a history of substance misuse, as recorded in their medical records
  • People who are pregnant or planning to become pregnant within the next 12 months
  • People who are currently taking part in another type 2 diabetes study
  • People who plan to stop attending the clinic within the next 12 months

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 7 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Antoinette Schoenthaler, NYU Langone Health

Phone: 732-501-9057

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
4 November 2025
Est. completion
31 March 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in Hemoglobin A1C (HbA1c)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov